logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
P

Peter C.C. Fong

Auckland City Hospital and University of Auckland
H指数:42
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]

勘误：Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析，来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]

European Journal of Cancer
IF7.1
2025-11-130
PRE
Arun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G

维布司妥利单抗与帕博利珠单抗联合给药于多西他赛预处理的转移性去势抵抗性前列腺癌患者：KEYNOTE-365研究G队列

European Urology Focus
IF5.6
2025-08-110
PREAI
Peter C. Fong; Mariusz Kwiatkowski; Alessandra Mosca; Begona P. Valderrama; Chunde Li; Yi-Hsiu Huang; Ahmed H. Zedan; Kamil Kuć; Pawel Wiechno; Brigitte Laguerre; Enrique Gonzalez-Billalabeitia; Mikhail Osipov; Didem Şener Dede; Jeffrey C. Goh; Gedske Daugaard; Pengfei Zhu; Kentaro Imai; Yingjie Liu; José A. Arranz Arija
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer

KEYLYNK-010研究中患者报告结局：帕博利珠单抗联合奥拉帕利与阿比特龙或恩扎卢胺治疗生物标志物未筛选、既往接受过治疗的转移性去势抵抗性前列腺癌患者

European Urology Oncology
IF9.3
2025-07-190
OAAI
Niven Mehra; Emmanuel S. Antonarakis; Se Hoon Park; Jeffrey C. Goh; Ray McDermott; Nuria Sala Gonzalez; Peter C. Fong; Richard Greil; Maria De Santis; Patricio Eduardo Yanez; Yi-Hsiu Huang; Stephen D. Begbie; Felipe Rey; Gero Kramer; Hiroyoshi Suzuki; Todd L. Saretsky; Sameer R. Ghate; Yi Cui; Christian Hosius; Evan Y. Yu
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果：来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

lancet
IF0
2025-07-160
PRE
Neeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者：来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果

lancet
IF0
2025-07-160
PRE
Karim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Rucaparib用于铂敏感、复发性卵巢癌的维持治疗：III期、随机、安慰剂对照ARIEL3试验的最终结果

European Journal of Cancer
IF7.1
2025-06-170
OA
Jonathan A. Ledermann; Amit M. Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I. Weberpals; Andrew R. Clamp; Giovanni Scambia; Alexandra Leary; Robert W. Holloway; Margarita Amenedo Gancedo; Peter C. Fong; Jeffrey C. Goh; David M. O’Malley; Deborah K. Armstrong; Susana Banerjee; Jesús García-Donas; Elizabeth M. Swisher; Robert L. Coleman
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌: 来自随机，安慰剂对照，III期TALAPRO-2研究的安全性分析

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-12-010
OAAI
Azad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschaebitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; Carles, Joan; Fay, Andre P.; Lin, Xun; Deannuntis, Liza; Di Santo, Nicola; Zielinski, Michael A.; Agarwal, Neeraj
Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study

talazoparib和enzalutamide在先前接受过雄激素受体通路抑制剂（ARPI）或多西他赛的mCRPC患者中的疗效：来自TALAPRO-2研究两个队列的事后分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Agarwal, N.; Azad, A. A.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Szczylik, C.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Oldenburg, J.; Lin, X.; Laird, D.; Kalac, M.; Kennedy, D.; Fizazi, K.
Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations

同源重组修复（HRR）缺陷人群中TALAPRO-2试验的血液学毒性发生率及其与HRR基因改变生殖系来源与体细胞来源的潜在关联

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Azad, A. A.; Agarwal, N.; Shore, N. D.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Saad, F.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Zschaebitz, S.; Piulats Rodriguez, J. M.; Yip, S. M.; Liu, G.; DeAnnuntis, L.; Lin, X.; Laird, D.; Kalac, M.; Fizazi, K.
Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100

阿维鲁姆单抗一线（1L）维持治疗在晚期尿路上皮癌（aUC）中的条件性生存和长期安全性：JAVELIN Bladder 100研究中接受≥1年或≥2年治疗患者的数据。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Grivas, P.; Park, S. H.; Voog, E.; Su, W-P.; Demey, W.; Fong, P. C.; Garcia, J. A.; Jacob, N.; Gerhold-Ay, A.; Tyroller, K.; Hoffman, J.; Bellmunt, J.; Powles, T. B.
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

TALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较

FUTURE ONCOLOGY
IF2.6
2024-07-121
OAAI
Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

Pembrolizumab和恩扎鲁他胺治疗经醋酸阿比曲酮预处理的转移性去势抵抗性前列腺癌患者: 1b/2期KEYNOTE-365研究的队列C

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-06-010
OA
Yu, Evan Y.; Berry, William R.; Gurney, Howard; Retz, Margitta; Conter, Henry J.; Laguerre, Brigitte; Fong, Peter C. C.; Ferrario, Cristiano; Todenhofer, Tilman; Gravis, Gwenaelle; Piulats, Josep M.; Emmenegger, Urban; Shore, Neal D.; Romano, Emanuela; Mourey, Loic; Li, Xin Tong; Poehlein, Christian H.; Schloss, Charles; Appleman, Leonard J.; Bono, Johann S. de
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D

帕博利珠单抗联合阿比特龙醋酸盐和泼尼松用于化疗初治转移性去势抵抗性前列腺癌患者：KEYNOTE-365研究D队列的结果

European Urology Oncology
IF9.3
2024-06-010
OAAI
Evan Y. Yu; Cristiano Ferrario; Mark D. Linch; Michael Stoeckle; Brigitte Laguerre; Jose A. Arranz; Tilman Todenhöfer; Peter C. Fong; Josep M. Piulats; William Berry; Urban Emmenegger; Loic Mourey; Anthony M. Joshua; Nataliya Mar; Leonard J. Appleman; Henry J. Conter; Gwenaelle Gravis; Xin Tong Li; Charles Schloss; Christian Poehlein; Johann S. de Bono
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (vol 30, pg 257, 2024)

一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验 (第30卷，257页，2024页)

NATURE MEDICINE
IF50
2024-01-311
OAAI
Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验

NATURE MEDICINE
IF50
2023-12-0440
OAAI
Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

Talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 治疗转移性去势抵抗性前列腺癌 (mCRPC): 通过同源重组修复 (HRR) 状态对来自TALAPRO-2的所有参与者队列进行亚组分析

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Matsubara, N.; Fizazi, K.; Azad, A. A.; Galceran, J. Carles; Fay, A. P.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Karsh, L. I.; Barthelemy, P.; Lin, X.; Healy, C. G.; Di Santo, N.; Zohren, F.; Agarwal, N.
Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA: Results from a phase III (TALAPRO-2) study

接受talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 与安慰剂 (PBO) 加ENZA的转移性去势抵抗性前列腺癌 (mCRPC) 和同源重组修复 (HRR) 突变男性的患者报告结局 (PROs): III期 (TALAPRO-2) 研究的结果

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Fay, A. P.; Fizazi, K.; Matsubara, N.; Azad, A. A.; Saad, F.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Jones, R. J.; Zschaebitz, S.; Oldenburg, J.; Shore, N. D.; Dunshee, C.; Galceran, J. Carles; Cislo, P.; Chang, J.; Healy, C. G.; Niyazov, A.; Agarwal, N.
Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2

同源重组修复 (HRR) 基因改变的种系 (g) 与体细胞 (s) 起源的探索以及与TALAPRO-2 HRR缺陷人群中抗肿瘤活性的潜在关联

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Yip, S. M.; Fizazi, K.; Matsubara, N.; Azad, A. A.; Joung, J. Y.; Fong, P. C.; Galceran, J. Carles; De Giorgi, U. F. F.; Jones, R. J.; Liu, G.; Fay, A. P.; Voog, E.; Zschaebitz, S.; Oldenburg, J.; Di Santo, N.; Healy, C. G.; Lin, X.; Laird, D.; Agarwal, N.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Talazoparib联合恩扎鲁他胺治疗一线转移性去势抵抗性前列腺癌 (TALAPRO-2): 一项随机、安慰剂对照、3期临床试验

LANCET
IF88.5
2023-07-01181
PRE
Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim

研究方向

暂未获取到该数据
J
Johann S. de Bono
H 指数:160论文数:2,491被引数:13.5万
N
Neal D. Shore
H 指数:84论文数:1,298被引数:4.5万
R
Robert J. Jones
H 指数:67论文数:431被引数:2.9万
N
Nobuaki Matsubara
H 指数:39论文数:463被引数:1.2万
A
Arun Azad
H 指数:51论文数:521被引数:1.3万
A
André P. Fay
H 指数:33论文数:256被引数:6,516
J
Joan Carles
H 指数:55论文数:717被引数:2.0万
K
Karim Fizazi
H 指数:123论文数:1,539被引数:8.3万
C
Curtis Dunshee
H 指数:15论文数:67被引数:1,763
X
Xun Lin
H 指数:30论文数:130被引数:4,955